Chiba, Japan

Hiroshi Namekawa


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 1989-1991

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hiroshi Namekawa: Innovator in Cerebrovascular Therapeutics

Introduction

Hiroshi Namekawa is a distinguished inventor based in Chiba, Japan. He has made significant contributions to the field of medicine, particularly in the development of therapeutic agents for cerebrovascular diseases. With a total of 2 patents, his work focuses on innovative solutions to treat critical health conditions.

Latest Patents

Hiroshi Namekawa's latest patents include the development of pyrazolone derivatives aimed at treating cerebrovascular diseases. One of his notable inventions is a 2-pyrazoline derivative, which is designed to address cerebral edemas during the acute stage of cerebral apoplexy. This compound features a unique formula where R¹ can be a pyridyl, a pyrazyl, or an alkoxy group, while R² can be a hydrogen atom, an alkyl, a pyridyl, a furyl, phenyl, or a substituted phenyl group. Additionally, he has created therapeutic agents that utilize a 2-pyrazoline derivative as the active ingredient, which helps regulate body circulation and protect ischemic lesions.

Career Highlights

Hiroshi Namekawa is currently employed at Mitsui Toatsu Chemicals, Incorporated, where he continues to innovate in the field of pharmaceuticals. His work has been pivotal in advancing treatments for cerebrovascular conditions, showcasing his commitment to improving patient outcomes.

Collaborations

Hiroshi collaborates with esteemed colleagues such as Hiroyuki Yamashita and Makoto Odate. Their combined expertise contributes to the ongoing research and development of effective therapeutic agents.

Conclusion

Hiroshi Namekawa's contributions to the field of cerebrovascular therapeutics highlight his role as a leading inventor. His innovative work continues to pave the way for advancements in medical treatments, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…